39434878|t|Erlotinib regulates short-term memory, tau/Abeta pathology, and astrogliosis in mouse models of AD.
39434878|a|Introduction: Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that is approved by the FDA to treat non-small cell lung cancer (NSCLC). Several membrane receptors, including EGFR, interact with amyloid beta (Abeta), raising the possibility that erlotinib could have therapeutic effects on Alzheimer's disease (AD). However, the effects of erlotinib on Abeta/tau-related pathology and cognitive function in mouse models of AD and its mechanisms of action have not been examined in detail. Methods: To investigate the effects of erlotinib on cognitive function and AD pathology, 3 to 6-month-old PS19 mice and 3 to 3.5-month-old 5xFAD mice and WT mice were injected with vehicle (5% DMSO + 10% PEG + 20% Tween80 + 65% D.W.) or erlotinib (20 mg/kg, i.p.) daily for 14 or 21 days. Then, behavioral tests, Golgi staining, immunofluorescence staining, western blotting ELISA, and real-time PCR were conducted. Results and discussion: We found that erlotinib significantly enhanced short-term spatial memory and dendritic spine formation in 6-month-old P301S tau transgenic (PS19) mice. Importantly, erlotinib administration reduced tau phosphorylation at Ser202/Thr205 (AT8) and Thr231 (AT180) and further aggregation of tau into paired helical fragments (PHFs) and neurofibrillary tangles (NFTs) in 3-month-old and/or 6-month-old PS19 mice by suppressing the expression of the tau kinase DYRK1A. Moreover, erlotinib treatment decreased astrogliosis in 6-month-old PS19 mice and reduced proinflammatory responses in primary astrocytes (PACs) from PS19 mice. In 3- to 3.5-month-old 5xFAD mice, erlotinib treatment improved short-term spatial memory and hippocampal dendritic spine number and diminished Abeta plaque deposition and tau hyperphosphorylation. Furthermore, erlotinib-treated 5xFAD mice exhibited significant downregulation of astrocyte activation, and treating PACs from 5xFAD mice with erlotinib markedly reduced cxcl10 (reactive astrocyte marker) and gbp2 (A1 astrocyte marker) mRNA levels and proinflammatory cytokine mRNA and protein levels. Taken together, our results suggest that erlotinib regulates tau/Abeta-induced AD pathology, cognitive function, and Abeta/tau-evoked astrogliosis and therefore could be a potent therapeutic drug for ameliorating AD symptoms.
39434878	0	9	Erlotinib	Chemical	MESH:D000069347
39434878	43	48	Abeta	Gene	11820
39434878	64	76	astrogliosis	Disease	MESH:D005911
39434878	80	85	mouse	Species	10090
39434878	96	98	AD	Disease	MESH:D000544
39434878	114	123	Erlotinib	Chemical	MESH:D000069347
39434878	130	162	epidermal growth factor receptor	Gene	13649
39434878	164	168	EGFR	Gene	13649
39434878	217	243	non-small cell lung cancer	Disease	MESH:D002289
39434878	245	250	NSCLC	Disease	MESH:D002289
39434878	291	295	EGFR	Gene	13649
39434878	325	330	Abeta	Gene	11820
39434878	362	371	erlotinib	Chemical	MESH:D000069347
39434878	406	425	Alzheimer's disease	Disease	MESH:D000544
39434878	427	429	AD	Disease	MESH:D000544
39434878	456	465	erlotinib	Chemical	MESH:D000069347
39434878	469	474	Abeta	Gene	11820
39434878	523	528	mouse	Species	10090
39434878	539	541	AD	Disease	MESH:D000544
39434878	644	653	erlotinib	Chemical	MESH:D000069347
39434878	680	682	AD	Disease	MESH:D000544
39434878	716	720	mice	Species	10090
39434878	750	754	mice	Species	10090
39434878	762	766	mice	Species	10090
39434878	798	802	DMSO	Chemical	MESH:D004121
39434878	809	812	PEG	Chemical	-
39434878	819	826	Tween80	Chemical	MESH:D011136
39434878	842	851	erlotinib	Chemical	MESH:D000069347
39434878	1059	1068	erlotinib	Chemical	MESH:D000069347
39434878	1163	1168	P301S	ProteinMutation	tmVar:p|SUB|P|301|S;HGVS:p.P301S;VariantGroup:0;OriginalGene:13548;CorrespondingGene:1859;CorrespondingSpecies:10090
39434878	1185	1189	PS19	CellLine	CVCL:9225
39434878	1191	1195	mice	Species	10090
39434878	1210	1219	erlotinib	Chemical	MESH:D000069347
39434878	1377	1400	neurofibrillary tangles	Disease	MESH:D055956
39434878	1402	1406	NFTs	Disease	MESH:D055956
39434878	1447	1451	mice	Species	10090
39434878	1500	1507	DYRK1A.	Gene	13548
39434878	1518	1527	erlotinib	Chemical	MESH:D000069347
39434878	1548	1560	astrogliosis	Disease	MESH:D005911
39434878	1581	1585	mice	Species	10090
39434878	1598	1613	proinflammatory	Disease	
39434878	1658	1662	PS19	CellLine	CVCL:9225
39434878	1663	1667	mice	Species	10090
39434878	1698	1702	mice	Species	10090
39434878	1704	1713	erlotinib	Chemical	MESH:D000069347
39434878	1813	1818	Abeta	Gene	11820
39434878	1880	1889	erlotinib	Chemical	MESH:D000069347
39434878	1904	1908	mice	Species	10090
39434878	2000	2004	mice	Species	10090
39434878	2010	2019	erlotinib	Chemical	MESH:D000069347
39434878	2037	2043	cxcl10	Gene	15945
39434878	2076	2080	gbp2	Gene	14469
39434878	2210	2219	erlotinib	Chemical	MESH:D000069347
39434878	2234	2239	Abeta	Gene	11820
39434878	2248	2250	AD	Disease	MESH:D000544
39434878	2286	2291	Abeta	Gene	11820
39434878	2303	2315	astrogliosis	Disease	MESH:D005911
39434878	2382	2384	AD	Disease	MESH:D000544
39434878	Negative_Correlation	MESH:D000069347	13649
39434878	Negative_Correlation	MESH:D000069347	13548
39434878	Association	11820	13649
39434878	Negative_Correlation	MESH:D000069347	MESH:D002289
39434878	Negative_Correlation	MESH:D000069347	MESH:D005911
39434878	Association	MESH:D002289	13649
39434878	Association	MESH:D000069347	11820
39434878	Association	MESH:D055956	13548
39434878	Negative_Correlation	MESH:D000069347	MESH:D000544
39434878	Association	MESH:D000069347	15945
39434878	Positive_Correlation	MESH:D000069347	MESH:D055956

